COMPOSITION FOR TREATMENT OF DIABETES

摘要

PURPOSE: A new therapeutic agent composition for diabetes containing one or more compounds selected from SJ-2030 and SJ-2031 separated from Carduus crispus L. and isoliovil as an effective ingredient is provided. These compounds exhibit excellent blood-glucose lowering actions in efficacy tests and higher safety than other drugs(tolbutamide) during oral or peritoneal administration in acute toxicity tests. CONSTITUTION: The diabetes therapeutic composition contains (7R, 8R, 8'R, 9'R)-4, 7, 4', 9'-tetrahydroxy-3, 3'-dimethoxy-Δ1, 3, 5, 1', 3', 5'-8.8', 9.0.9'-lignan(SJ-2030) of formula 1, (8R, 8'R, 9'R)-4, 7, 4', 9'-tetrahydroxy-3, 3'-dimethoxy-Δ1, 3, 5, 1', 3', 5'-8.8', 9.0.9'-lignan(SJ-2031) of formula 2 and 4, 7, 4', 9'-tetrahydroxy-3, 3'-dimethoxy-Δ1, 3, 5, 1', 3', 5'-8.8', 9.0.9'-lignan(isoliovil) of formula 3. For an example, 10kg Carduus crispus L. is extracted in 30L methanol for 24hr three times, the extract is suspended in 2L distilled water and subjected to solvent fraction at room temperature to produce SJ-2030.